SCHEMBL2016891

SCHEMBL2016891

CCOc1cccc(CN(C)c2nnc(-c3c(C)cccc3C)c3ccccc23)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.39
CSF1R P07333 7/20 0.39
MAPT P10636 3/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GBA1 P04062 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TSHR P16473 1/20 0.38
BCHE P06276 2/20 0.38
TP53 P04637 2/20 0.36
CYP3A4 P08684 1/20 0.36
EGFR P00533 2/20 0.36
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
CETP P11597 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2021464 0.89 SMN1; SMN2 (0.49) CSF1RMAPTLMNAKDM4EALDH1A1
SCHEMBL2017270 0.86 CRHR1 (0.41) DHFRMAPTTSHRBCHETP53
SCHEMBL2019715 0.82 ALDH1A1 (0.48) CSF1RMAPTLMNAKDM4EALDH1A1
SCHEMBL2016765 0.76 GABRA1 (0.46) CSF1RMAPTLMNAKDM4EALDH1A1
SCHEMBL2016512 0.75 GBA1 (0.48) ALDH1A1GBA1HPGDSMN1; SMN2L3MBTL1
SCHEMBL2020985 0.74 CSF1R (0.43) CSF1RLMNAKDM4ESMN1; SMN2GABRA1
SCHEMBL2017558 0.73 CSF1R (0.43) CSF1RLMNAALDH1A1EGFRGABRA1
SCHEMBL2019830 0.72 CSF1R (0.40) CSF1REGFRGABRA1GABRG2GABRB3
SCHEMBL2022779 0.70 SCN8A (0.35) CSF1RKDM4EALDH1A1TSHRCYP3A4
SCHEMBL2019153 0.68 EGFR (0.41) HPGDTSHREGFRGABRA1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US claimed
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines MMP25, MMP9, MMP3 DHFR 714/4885CSF1R 1219/4885MAPT 3362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.